CatalinaS DVillanuevaMD

PubMed

• Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
  Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, Finkelstein D, Pickrell P, Kirstein J, Yut C, Blair R, Clifford RA, Dunn M, Campbell JD, Montef...> ;The New England journal of medicine. 2022-05-11

Journal Articles

• Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age  
  C. Buddy Creech, M.D., M.P.H., Evan Anderson, M.D., Vladimir Berthaud, M.D., M.P.H., Inci Yildirim, M.D., Ph.D., et al., for the KidCOVE Study Group*, New England of Medicine Journal, 5/26/2022
• Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis  
  Hayden FG, Belche R, Villanueva C, ADIS International LTD, 2/1/2004
• Management of Influenza in Households:A Prospective,Randomized Comparison of Oseltimivir Treatment With or Without Postexposure Prophylaxis.Adis International Ltd,May ...  
  Hayden FG, Belche R, Villanueva C, ADIS International LTD, 5/15/2003
• The Efficacy and Tolerability of Moxifloxacin Compared to Trovafloxacin in the Treatment of Acute Sinusitis.Today's Therapeutic Trends17(4):303-319,1999  
  Baz MN, Jannetti W , Villanueva C, Today’s Therapeutic Trends, 10/15/1999
• Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group.  
  Burke, Villanueva, Mariano, Clinical Therapeutics, 10/1/1999
• Join now to see all

Abstracts/Posters

• Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group.
  Burke T, Villanueva C, Clinical Therapeutics, 10/15/1999